Ellevest Inc’s Immuneering IMRX Stock Holding History

Ellevest Inc’s Portfolio IMRX Stock Details IMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-7	Closed	–	–	1716
2022 Q2	$0	Buy	+7	New	+$37	﹤0.01%	1519

Other funds holding IMRX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BSW

Buckingham Strategic Wealth Clayton, Missouri $9.66B AUM 15.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $123B AUM 34.51% 1-Year Est. Return

Ellevest Inc's IMRX Position: Q3 2022 in Review

Ellevest Inc sold out of Immuneering (IMRX) in Q3 2022, closing a stake of 7 shares.

Ellevest Inc first reported a position in IMRX in Q2 2022 and held it in 1 quarter. The position peaked at $0 in Q2 2022. 32 funds tracked by Wall St. Rank hold IMRX as of Q3 2022.

Ellevest Inc reported no remaining Immuneering position as of Q3 2022 after selling out during the quarter.
Ellevest Inc sold 7 Immuneering shares in Q3 2022.
Ellevest Inc first reported a position in Immuneering in Q2 2022 and held it in 1 quarter.
Ellevest Inc's Immuneering position peaked at $0 in Q2 2022.
32 funds tracked by Wall St. Rank held Immuneering as of Q3 2022.

Based on Ellevest Inc's 13F filing for Q3 2022, filed 2 Nov 2022.